Recent Updates
Recently added Catalysts

Moxidex otic

Phase 3

Acute Otitis Media | Small molecule | ENT |Alcon Inc.|Last Updated: Dec 3, 2012

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials3
Total Enrollment1,990
FDA Designations
No designations recorded
Clinical trial landscape

Moxidex otic · 4 trials · 2 indications

Phase 3 3Phase 2 1
NCT00750633A Phase III Study of an Otic Formulation in Acute Otitis ExternaAcute Otitis Externa
COMPLETED990 Analytics
NCT00579189Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy TubesAcute Otitis Media
COMPLETED776 Analytics
NCT00578474A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy TubesAcute Otitis Media
COMPLETED911 Analytics
PHASE3COMPLETED
A Phase III Study of an Otic Formulation in Acute Otitis Externa
Acute Otitis ExternaUnlock trial analytics
PHASE3COMPLETED
Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes
Acute Otitis MediaUnlock trial analytics
PHASE3COMPLETED
A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes
Acute Otitis MediaUnlock trial analytics
Study Endpoints
Primary Endpoints
Clinical Cure
Day 3
Time to cessation of otorrhea as recorded by the parent or guardian via a patient diary
From baseline
Clinical cure rate at the test of cure visit as determined by the investigator
From baseline
Secondary Endpoints
Microbiological Success
Day 12
Clinical cure rate
From baseline
Microbiological outcome
From baseline
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
MoxidexEXPERIMENTALMoxidex otic solution
MoxifloxacinACTIVE_COMPARATORMoxifloxacin otic solution
DexamethasoneACTIVE_COMPARATORDexamethasone phosphate otic solution
FLOXINACTIVE_COMPARATOROfloxacin otic solution
TT onlyOTHERTympanostomy tubes only
Interventions
NameTypeDescription
Moxidex otic solutionDRUG4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Moxifloxacin otic solutionDRUG4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Dexamethasone phosphate otic solutionDRUG4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
Tympanostomy tubesDEVICETubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
Ofloxacin otic solutionDRUG5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Clinical diagnosis of AOE based on clinical observation and of presumed bacterial origin * A minimum combined score of ≥4 in at least 1 affected ear at the Day 1 exam for tenderness, erythema, and edema * Other protocol-defined inclusion criteria may apply Exclusion Criteria:...

Unlock Eligibility Criteria